Google Ads 'Unapproved Substances': How to Tell a Copy Problem From a Product Problem
Google's “Unapproved substances” label flags the product or ingredient in your ad, not just the wording — so a rewrite fixes some cases and does nothing for others. This guide covers what the policy actually prohibits (ephedra, hCG for weight loss, DHEA outside US targeting, named products), how to diagnose the root cause before you edit or appeal, the appeal limits, and what a copy check can and cannot do.
Seeing “Unapproved substances” on a disapproved ad in your Google Ads account tells you something specific, and it is usually not about your punctuation. The label sits under Google’s Healthcare and medicines policy and points at the product or substance your ad promotes, not the way you phrased one headline. That distinction decides your next move: a wording problem can often be fixed with a rewrite, while a product-level prohibition cannot be edited away. This guide shows how to tell the two apart, what Google actually lists as prohibited, and what your real options are once an ad is flagged.
What the “Unapproved substances” label actually means
Google’s policy opens with a blunt line: “Google doesn’t allow the promotion of certain products, regardless of any claims of legality.” The label is not a comment on tone or claims style. It means Google has classified the thing you are advertising as one it will not promote at all, or one it will promote only in certain locations and only for advertisers who have been approved and certified.
Two consequences follow from that definition:
- Rewriting copy does not clear a product-level ban. If the product itself is prohibited, a cleaner headline changes nothing. You have to change the product, the ingredient, or the targeting.
- Wording can still matter inside the allowed set. For products that are not on a prohibited list, the claims you write (implying prescription-drug strength, or a cure for a disease) can push an ad into this policy or its neighbours.
One useful reassurance for scale: Google states that violations of this particular policy “won’t lead to immediate account suspension without prior warning,” and that a warning is issued at least 7 days before any suspension. That is different from Google’s most serious (“egregious”) policies, such as unauthorized pharmacies and prescription opioid painkillers, where accounts are suspended on detection without prior warning. Unapproved substances is a warning-first policy, which gives you room to diagnose the cause — but it is not a label to leave in place.
Copy problem or product problem? The first question to answer
Almost every “Unapproved substances” disapproval resolves down to one of two root causes. Sorting your case into the right column is the whole task, because the fix is different.
| What triggered the label | Type of problem | Can a copy rewrite fix it? |
|---|---|---|
| A named product on Google’s non-exhaustive list, or a banned ingredient such as ephedra | Product | No — remove the product or ingredient |
| hCG promoted for weight loss or weight control, or alongside anabolic steroids | Product / claims | No for the weight-loss framing — drop the product or the positioning |
| A DHEA product in a campaign that targets outside the United States | Targeting | Partly — restrict targeting to the US, or remove the product |
| Copy that implies the product is as effective as a prescription drug or controlled substance | Copy (sometimes product) | Often yes — if the underlying product is legitimate |
| Marketing a non-government-approved product as safe or effective for preventing, curing, or treating a disease | Copy and/or product | Sometimes — remove the disease claim; a genuine unapproved drug is still a product problem |
| A product that has been subject to government or regulatory action or warning | Product | No — documentation and status, not wording |
| A product name confusingly similar to an unapproved pharmaceutical, supplement, or controlled substance | Product / name | No — rename or drop it |
The pattern is that the top and bottom rows are not fixable with better sentence structure, while the middle rows are exactly the kind of issue a wording review is built to catch. A checker that only looks at text cannot move a product off Google’s list; it can only help you avoid the wordings that trigger a label on products that are otherwise allowed. ByeRisk’s ad compliance checks are built for that middle row: they review the creative you submit and name the rule behind each finding, while stating plainly that account, landing-page and verification issues follow separate processes.
What Google actually lists as prohibited
The policy is short, so read it directly rather than trusting a summary. Google will not promote:
- Any item on its non-exhaustive list of unapproved pharmaceuticals and supplements — a long, literally named list that includes weight-loss and “herbal” supplements (for example Magic Slim Tea, Pai You Guo Slim Tea, OxyElite Pro) and bodybuilding products (for example superdrol, trenadrol). Because the list is non-exhaustive, absence from it is not permission.
- Products that contain ephedra.
- Products containing human chorionic gonadotropin (hCG) in relation to weight loss or weight control, or when promoted together with anabolic steroids.
- Herbal and dietary supplements with active pharmaceutical or dangerous ingredients.
- Products that imply they are as effective as prescription drugs or controlled substances.
- Non-government-approved products marketed in a way that implies they are safe or effective for preventing, curing, or treating a particular disease or ailment.
- Products that have been subject to any government or regulatory action or warning.
- Products with names confusingly similar to an unapproved pharmaceutical or supplement, or a controlled substance.
- Dehydroepiandrosterone (DHEA) products, except in campaigns targeting the United States.
Google adds that this is not an exhaustive set and points to LegitScript for additional information on the unapproved or misleading pharmaceuticals and supplements it monitors. The practical reading: the trigger is often the product, and the copy is where it becomes visible.
Why location and certification decide many cases
Healthcare content is not simply allowed or banned. Some of it is permitted only in certain countries, and only for advertisers who have applied and been approved. Three details matter most for US advertisers:
| Case | What Google requires |
|---|---|
| DHEA products | Allowed only when the campaign targets the United States |
| US online pharmacies and telemedicine | Certification plus accreditation such as LegitScript or NABP, before ads can serve |
| Cannabidiol (CBD) | FDA-approved pharmaceutical CBD needs Google certification and is limited to California, Colorado, and Puerto Rico; non-pharmaceutical topical CBD needs LegitScript certification first |
When an ad is allowed but restricted, Google may label it “Eligible (limited)” instead of approved outright — it can run, but only where the policy permits. That label can also appear when your site content contains terms tied to a regulated industry even if your product is compliant, so a limited status is not always a violation you can edit out.
How to review before you submit
Run this in order, and stop at the first “no” — because a product-level problem makes the rest of the checklist irrelevant:
- 1. Name the substance and the product. List every active ingredient and the exact product name that appears in the ad and on the landing page.
- 2. Check the list. Compare each ingredient against the ephedra, hCG, and DHEA rules, and each product name against Google’s named list. Treat a confusingly similar name as a flag.
- 3. Check the product’s status. Has it been recalled, warned, or subject to a regulatory or government action? That alone can put it in scope.
- 4. Read the claims, not the vibe. Look for anything implying prescription-drug strength, and anything that presents a non-approved product as safe or effective for preventing, curing, or treating a disease.
- 5. Match copy to the right platform layer. Google’s rules are not Meta’s rules. A line that is fine in one account can be the trigger in another — see how health-claim rejections differ on Meta — so check against the platform you are actually running on.
- 6. Fix what is copy, and drop what is product. Rewrite the claim where that is the cause; remove the substance or product where it is not.
Worked examples (hypothetical)
These are illustrative, not real customer results.
Example 1 — a claims problem. Headline: “Clinically proven to burn fat like a prescription fat-burner.” The product is an ordinary supplement, but the line implies it is as effective as a prescription drug, which the policy names. Fix: describe what the product does without the prescription comparison; a text review flags the comparison before you submit.
Example 2 — a product problem. The ad promotes an “hCG diet drop” for weight loss. Because hCG for weight loss is prohibited regardless of wording, no rewrite helps. Fix: remove the product, not the sentence.
Example 3 — a targeting problem. A DHEA product is advertised in a campaign that targets Europe and the US. DHEA is permitted only in US-targeted campaigns. Fix: separate the targeting so the DHEA ad runs in the US only, or drop it from the non-US campaign.
If the ad is already disapproved: edit or appeal
Once the label is applied, Google gives you two paths, and the reason for the disapproval decides which one applies.
- Edit the ad or its destination. The ad is reviewed again automatically after you save. If the cause was a landing page or destination issue, you may need to change the page or point the ad at a different URL.
- Appeal the policy decision. Choose “Dispute decision” or “Made changes to comply with policy.” Appeals are not unlimited: each ad is limited to 3 appeals, appeals should be spaced at least 24 hours apart to avoid duplicate statuses, and starting July 21, 2026 you cannot appeal an in-account policy decision from more than 6 months earlier.
Google’s own guidance is not to resubmit the same appeal repeatedly; if a fixed appeal fails or is marked duplicate, make a minor edit to the ad text or final URL to trigger a fresh crawl. And remember that an appeal is only worth filing when the product itself is allowed — disputing a banned substance wastes one of your three attempts.
What a copy review can and cannot do
Be clear-eyed about the boundary, because it is where most “will this get my ad approved?” questions go wrong.
- It can show which wording in your headline, description, or primary text matches a policy or a named product rule, so you fix the right line before submitting. The free Ad Compliance Checker runs that rule library on pasted copy, and a separate Supplement Claim Checker helps separate structure/function claims from disease claims under FDA rules.
- It cannot take a product off Google’s prohibited list, satisfy a LegitScript or NABP requirement, complete a Google healthcare certification, or run your account verification.
- It does not cover your landing page, your targeting, your ad account status, or claims written inside an image. Those follow separate platform processes.
- A clean check is not approval. Google reviews images, targeting, and the destination too, and it makes the final call.
That is why the honest first step on an “Unapproved substances” flag is diagnosis, not rewriting: confirm whether you have a copy problem you can edit or a product problem you cannot.
Frequently asked questions
Is “Unapproved substances” the same as a supplement ban?
No. It applies to a defined set of prohibited products — named supplements, ephedra, hCG for weight loss, DHEA outside US campaigns, and others — plus claims that imply prescription-drug strength or a disease cure. Many supplements are not on the list; the policy targets specific products and ingredients, not all supplements.
Will Google suspend my account immediately?
Not under this policy. Google says a warning is issued at least 7 days before any suspension for unapproved substances. Account suspensions without prior warning apply to Google’s egregious policies, such as unauthorized pharmacies and prescription opioid painkillers.
Can I still advertise DHEA or CBD in the US?
DHEA is allowed only in campaigns that target the United States. For CBD, FDA-approved pharmaceutical CBD advertisers need Google certification and are limited to California, Colorado, and Puerto Rico, and non-pharmaceutical topical CBD advertisers need LegitScript certification first. Compliant wording does not replace those certifications.
Does rewriting the headline clear an “Unapproved substances” disapproval?
Only when the cause is your copy. If the flagged item is the product or an ingredient, a rewrite changes nothing — you have to remove the substance or change the targeting. Confirm the root cause before spending one of your appeals.
How many times can I appeal?
Each ad is limited to 3 appeals, and Google recommends waiting at least 24 hours between appeals to avoid duplicate statuses. From July 21, 2026, in-account appeals are not available for policy decisions made more than 6 months earlier.
Sources
Official pages this article relies on. Policies change, so check the source before you act on it.
- Google Ads · Unapproved substances
- Google Ads · Unapproved pharmaceuticals and supplements (list)
- Google Ads · Healthcare and medicines
- Google Ads · Fix a disapproved ad or appeal a policy decision
- Google Ads · Eligible (limited): Definition
- LegitScript (referenced by Google for monitored pharmaceuticals and supplements)
Let automated checks keep track of these rules
Sign up to receive 100 credits and check English copy, videos, and images, with the regulation or platform rule behind every flag.
Sign up for free
